GPCR earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -19.09. Updated 2026-07-23.
Structure Therapeutics (GPCR) Research Hub
Structure Therapeutics (GPCR) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 38.66 USD (-6.23%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -19.09, market cap 2.84B. This hub links to the full technical, earnings and options research available for GPCR.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 38.66 USD (-6.23%) |
| 52-week range | 38.1 USD – 57.07 USD |
| Trend regime | Range |
| 14-day RSI | 20 (Oversold) |
| Trailing P/E | -19.09 |
| Market cap | 2.84B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for GPCR
Covered Call on GPCR: how it works, illustrative setup around the real 38.66 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GPCR: how it works, illustrative setup around the real 38.66 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GPCR: how it works, illustrative setup around the real 38.66 USD price, max profit/loss, breakeven and when to use it. Educational.
GPCR technical analysis: range, last 38.66 USD, RSI 20, 52w range 38.1 USD–57.07 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is GPCR in?
Structure Therapeutics (GPCR) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is GPCR in an uptrend or downtrend?
As of 2026-09-11, GPCR is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GPCR's trailing P/E ratio?
GPCR's trailing P/E is -19.09, with a market cap of 2.84B. See the earnings research page for full valuation detail.
When does GPCR next report earnings?
GPCR is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.39 USD.